Magrolimab plus Azacitidine Is Safe and Efficacious in High-Risk MDS

Cancer Discov. 2023 Mar 17;OF1. doi: 10.1158/2159-8290.CD-RW2023-040. Online ahead of print.

Abstract

This combination was safe and met its primary efficacy endpoint of complete remission rate.